Bone Biologics (NASDAQ:BBLG) Announces Quarterly Earnings Results

by · The Markets Daily

Bone Biologics (NASDAQ:BBLG – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04), FiscalAI reports.

Bone Biologics Stock Performance

BBLG stock traded down $0.02 during midday trading on Friday, reaching $0.66. The stock had a trading volume of 167,161 shares, compared to its average volume of 142,196. The firm has a fifty day simple moving average of $1.19 and a two-hundred day simple moving average of $1.25. Bone Biologics has a 52-week low of $0.62 and a 52-week high of $4.13. The stock has a market cap of $1.19 million, a PE ratio of -0.29 and a beta of 0.92.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a report on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on BBLG

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Bone Biologics stock. DRW Securities LLC increased its position in shares of Bone Biologics Corp. (NASDAQ:BBLG – Free Report) by 113.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. 34.30% of the stock is currently owned by institutional investors and hedge funds.

About Bone Biologics

(Get Free Report)

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.

Featured Stories